vs
Side-by-side financial comparison of Metalpha Technology Holding Ltd (MATH) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.0M, roughly 1.1× Metalpha Technology Holding Ltd). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -24.0%, a 99.7% gap on every dollar of revenue.
Metalpha Technology Holding LtdMATHEarnings & Financial Report
Metalpha Technology Holding Ltd is a global fintech firm specializing in digital asset wealth management, institutional-grade crypto investment services, and Web3 ecosystem infrastructure support. It serves professional investors, financial institutions, and high-net-worth clients across Asia, North America and Europe, with core segments including structured digital asset products, risk management solutions and DeFi technology development.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
MATH vs XLO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $13.7M |
| Net Profit | $-2.9M | $10.4M |
| Gross Margin | 28.3% | — |
| Operating Margin | -24.2% | -86.5% |
| Net Margin | -24.0% | 75.7% |
| Revenue YoY | -39.0% | — |
| Net Profit YoY | -147.7% | 179.1% |
| EPS (diluted) | $-0.07 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | $12.0M | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | $24.8M | $2.9M | ||
| Q3 24 | $19.7M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $-2.9M | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | $9.8M | $-13.3M | ||
| Q3 24 | $6.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | 28.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 85.7% | — | ||
| Q3 24 | 49.5% | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | -24.2% | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | 39.3% | -472.7% | ||
| Q3 24 | 38.9% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | -24.0% | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | 39.6% | -452.7% | ||
| Q3 24 | 30.7% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | $-0.07 | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | $0.25 | $-0.18 | ||
| Q3 24 | $0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.1M | $137.5M |
| Total DebtLower is stronger | $101.2K | — |
| Stockholders' EquityBook value | $35.1M | $35.3M |
| Total Assets | $413.8M | $154.7M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $10.1M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | $6.9M | $89.1M | ||
| Q3 24 | $3.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | $101.2K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $188.0K | — | ||
| Q3 24 | $275.1K | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | $35.1M | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | $36.6M | $10.7M | ||
| Q3 24 | $25.3M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | $413.8M | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | $246.8M | $103.7M | ||
| Q3 24 | $237.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.01× | — | ||
| Q3 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $3.3M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | $16.2M | $29.0M | ||
| Q3 24 | $-16.1M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q3 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q3 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.64× | — | ||
| Q3 24 | -2.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
